UBS Group
EPRX

UBS Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

UBS Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.52M Buy
762,635
+542,611
+247% +$4.37M ﹤0.01% 3982
2025
Q4 		$1.66M Buy
220,024
+124,268
+130% +$766K ﹤0.01% 5131
2025
Q3 		$565K Buy
95,756
+58,257
+155% +$317K ﹤0.01% 6002
2025
Q2 		$216K Sell
37,499
-13,700
-27% -$52.6K ﹤0.01% 6669
2025
Q1 		$168K Buy
51,199
+23,199
+83% +$80.1K ﹤0.01% 6658
2024
Q4 		$88.8K Sell
28,000
-5,000
-15% -$14.8K ﹤0.01% 6949
2024
Q3 		$86.8K Buy
33,000
+3,410
+12% +$8.97K ﹤0.01% 6456
2024
Q2 		$76.3K Buy
+29,590
New +$82.3K ﹤0.01% 6362

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

UBS Group's EPRX Position: Q1 2026 in Review

UBS Group increased its Eupraxia Pharmaceuticals (EPRX) stake by 247% in Q1 2026, buying an estimated $4.37M and bringing the position to 762,635 shares worth $5.52M. The position accounts for ﹤0.01% of the portfolio, ranked #3982.

UBS Group first reported a position in EPRX in Q2 2024 and has held it in 8 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • UBS Group held 762,635 shares of Eupraxia Pharmaceuticals worth $5.52M as of Q1 2026.
  • UBS Group bought 542,611 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $4.37M.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3982 holding.
  • UBS Group first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.